Articles related to Oncology, Surgical

A phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab followed by surgery to adjuvant nivolumab alone in resectable stage III melanoma patients found a significantly higher event-free survival rate in the neoadjuvant group. This suggests that pre-surgical immunotherapy could lead to better patient outcomes.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

The oncologist shortage, especially in rural areas, has reached a critical level, necessitating innovative solutions such as medical school debt repayment and congressional intervention to ensure comprehensive cancer care delivery across the United States.

An AI-powered test using dried blood spots can diagnose pancreatic, gastric, and colorectal cancers in minutes with 82–100% sensitivity, offering a cost-effective alternative for low-income regions.